Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The narrow therapeutic index of tacrolimus demands precise dose optimization to maintain therapeutic efficacy while minimizing toxicity, underscoring the necessity for reliable analytical techniques to accurately measure drug concentrations in biological matrices. In this study, we developed an ultrahigh-performance liquid chromatography coupled with quadrupole-orbitrap mass spectrometry method for quantifying tacrolimus in plasma. This approach employed an Acquity UPLC BEH C column, leveraging a gradient elution of methanol (A) and water with 0.1% formic acid (B) to ensure meticulous separation of tacrolimus and the internal standard, ascomycin. Operating in positive ionization mode, the system utilized full MS/dd-MS2 scans, capturing comprehensive data for heightened analytical accuracy and precision. The method demonstrated a broad linear range of 0.5 to 500 μg/L, with a low quantification limit of 0.5 μg/L. Notably, it achieved exceptional reproducibility and accuracy, with relative standard deviations and errors below 6%, complemented by consistent extraction efficiencies for tacrolimus at 84.78% to 97.15%. This study successfully showcases an advanced analytical platform for the meticulous quantification of tacrolimus, seamlessly integrating into pharmacokinetic investigations following a 1.2 mg/kg oral dose in rats. The method's deployment revealed its exceptional suitability for capturing intricate pharmacokinetic profiles, underscoring its value in preclinical drug disposition studies.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bmc.70164DOI Listing

Publication Analysis

Top Keywords

quantification tacrolimus
8
tacrolimus
6
efficient quantification
4
tacrolimus rat
4
rat plasma
4
plasma ultra-high
4
ultra-high performance
4
performance lc-q-orbitrap
4
lc-q-orbitrap precision
4
precision pharmacokinetic
4

Similar Publications

Chronic High Epstein-Barr Viral Load Carriage Is Positively Correlated With Tacrolimus Intra-Patient Variability After Pediatric Liver Transplantation.

J Med Virol

August 2025

Department of Hepatobiliary Surgery Children's Hospital of Chongqing Medical University, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.

Chronic high Epstein-Barr virus (EBV) load (CHL) carriage has been closely associated with EBV infection after pediatric liver transplantation. Elevated tacrolimus (Tac) blood concentrations increased the risk of EBV-associated diseases. Tacrolimus intra-patient variability (Tac-IPV) help predict poor outcomes.

View Article and Find Full Text PDF

Rationale: Immunotactoid glomerulopathy (ITG) is a rare glomerular disease characterized by protein deposition in hollow microtubules on electron microscopy. Patients may present with proteinuria, hematuria, hypertension, and renal insufficiency, and some patients even progress to end-stage renal disease (ESRD). In patients with ESRD, ITG recurs in more than 50% of patients after kidney transplantation; however, there is no clear treatment plan for these patients owing to the limited number of reported cases.

View Article and Find Full Text PDF

Association of intrapatient tacrolimus variability and concentration-to-dose ratio with outcomes in pediatric kidney transplantation.

Pediatr Nephrol

July 2025

Department of Pediatrics I, Medical Faculty, University Children's Hospital, Heidelberg University, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.

Background: Data on the relevance of tacrolimus intrapatient variability (TacIPV) and concentration-to-dose ratio (C/D ratio) as an approximation of tacrolimus metabolism for predicting outcomes in pediatric kidney transplant (pKTx) recipients are scarce.

Methods: We conducted a multicenter retrospective study of 255 pKTx recipients from the CERTAIN registry. TacIPV was quantified as the coefficient of variation (CV%) during months 6-12 post-transplant.

View Article and Find Full Text PDF

Objectives: Tacrolimus has been a cornerstone of immunosuppressive therapy over the past two decades. Due to its narrow therapeutic window and pharmacokinetic variability, drug monitoring is vital for enhancing the efficacy and safety during therapy. In the present study, we evaluated the analytical performances of the MAGLUMI Tacrolimus assay based on chemiluminescent immunoassay (CLIA), and compared with LC-MS/MS and the previously validated ARCHITECT Tacrolimus assay based on chemiluminescent microparticle immunoassay (CMIA).

View Article and Find Full Text PDF

Immunosuppressants are essential for preventing allograft rejection; however, they require therapeutic drug monitoring to maintain efficacy and to prevent severe complications such as opportunistic infections. Calcineurin inhibitors (CIs) are primarily distributed in red blood cells, whereas mycophenolic acid (MPA) and its metabolites are found in plasma. These differences necessitate separate analyses for each drug, increasing laboratory workload, analytical complexity, and patient burden.

View Article and Find Full Text PDF